Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

173.46
-6.3350-3.52%
Volume:346.17K
Turnover:60.89M
Market Cap:10.23B
PE:-53.44
High:179.96
Open:176.86
Low:173.23
Close:179.79
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:0.60
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:14.99
PE(LYR):-52.85

Loading ...

Movement Alert|Glaukos Rises 5.07% in Regular Trading, Pipeline Milestone and Earnings Optimism Fuel Rally

Market Focus
·
Jul 30

Glaukos Coverage Assumed by UBS at Neutral vs Previous Rating of Buy

Dow Jones
·
Jul 29

UBS Downgrades Glaukos to Neutral From Buy, $150 Price Target

MT Newswires Live
·
Jul 28

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

TIPRANKS
·
Jul 28

Glaukos Completes Enrollment in 510(k) Pivotal Study of Preserflo MicroShunt for Advanced Glaucoma Patients

Reuters
·
Jul 27

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for Preserflo™ Microshunt

THOMSON REUTERS
·
Jul 27

Earning Preview: Glaukos revenue is expected to increase by 30.68% this quarter, and institutional views are bullish

Earnings Agent
·
Jul 22

Glaukos CFO Alex R. Thurman Disposes of USD 1.6 Million in Common Shares

Reuters
·
Jul 22

Glaukos (GKOS) Could Be 1% Undervalued After Its Pipeline Growth Narrative

Simply Wall St.
·
Jul 17

Glaukos is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 17

Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating

MT Newswires Live
·
Jul 16

Mobia Medical Names Reza Zadno to Board as Independent Director

Reuters
·
Jul 16

Glaukos CFO Alex R. Thurman Sells 10,000 Shares for $1.55 Million

Reuters
·
Jul 14

Glaukos Chief Development Officer Tomas Navratil Disposes of 716 Shares for $99,571.96

Reuters
·
Jul 09

Glaukos is Maintained at Buy by Citigroup

Dow Jones
·
Jul 08

Press Release: Glaukos to Release Second Quarter 2026 Financial Results After Market Close on July 29

Dow Jones
·
Jul 08

Glaukos price target raised to $175 from $162 at Citi

TIPRANKS
·
Jul 08

Glaukos: Favorable iDose Reimbursement Outlook and Epioxa Launch Drive Attractive Risk-Reward, Supporting Buy Rating

TIPRANKS
·
Jul 08

Citi Sticks to Its Buy Rating for Glaukos (GKOS)

TIPRANKS
·
Jul 08

Glaukos Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 06